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total cost, quality-adjusted life years (QALYs), cumulative incidence of cirrhosis, 
decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and liver-related 
deaths (LRD). We also projected the number of new HCV infections in society due to 
HCV-infected people released from prisons. Results: The total costs under no and 
5YR screening were $6.9 million and $8.3 million per 10,000 people, respectively for 
30-year simulation. The corresponding QALYs were 190,428 and 190,462, respectively. 
The incremental cost-effectiveness ratio of 5YR screening was $43,000 per QALY. In 
comparison with no screening, 5YR screening can avoid 136,000 new HCV infections 
in the next 30 years, where 71% of these infections can be attributed to infected per-
sons released from prisons back in the society. The 5-year screening can also reduce 
the cumulative incidence of DC, HCC, LT and LRD by 14-17%. ConClusions: HCV 
screening followed by treatment in prisons is cost-effective at $50,000 willingness-
to-pay. Resources spent in prisons can substantially reduce the burden of HCV in 
both prisons and the society at large.
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objeCtives: The optimal management of patients with suspected biliary obstruc-
tion remains unclear, and includes the possible performance of magnetic resonance 
cholangiopancreatography (MRCP) and endoscopic retrograde cholangiopancrea-
tography (ERCP). We completed a medical effectiveness randomized trial comparing 
an ERCP-first to a MRCP-first approach in patients with suspected bile duct obstruc-
tion. Methods: The management strategies are based on a medical effectiveness 
trial of 257 patients over a 10-month follow-up period. Direct and indirect costs were 
included, adopting a societal perspective. The cost values are expressed in 2012 
Canadian dollars. Results: Direct costs attributable to visits were CAN$5350 in the 
ERCP and CAN$5750 in the MRCP group. The procedures costs were CAN$233,852 
and CAN$267,952 for the ERCP and MRCP groups, respectively. Second procedures 
were incurred twice more in the MRCP than in the ERCP group. Direct costs of com-
plications amounted to CAN$207,708 (ERCP group) and CAN$252,347 (MRCP group). 
Total direct costs added up to CAN$446,910 for the 126 patients in the ERCP-first 
strategy and CAN$525,689 for the 131 MRCP-first patients. With regards to indirect 
costs, MRCP group patients spent more days in scheduled GI visits (8 days) and 
hospitalizations (49 days), but less days in procedures (18 days) and in time away 
from activity of daily living (44 days). Overall total indirect costs were quite similar 
(ERCP-first CAN$92,219 versus MRCP-first CAN$90,912). ConClusions: This cost 
analysis suggests only a small difference in total costs, favoring the ERCP-first group, 
and is principally attributable to procedures and hospitalizations with little impact 
from indirect cost measurements.
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objeCtives: A decision-analytic Markov model was developed to predict the 
health outcomes of using sofosbuvir (SOF) -based regimen compared with cur-
rent treatment options for patients who are co-infected with hepatitis C (HCV) 
and HIV. Methods: The analysis modeled a cohort of treatment-naïve genotype 1 
patients co-infected with HIV and HCV with a mean age of 54 years and 25% with 
cirrhosis. The model was evaluated from a US third-party payer perspective for a 
lifetime time horizon. SOF+pegylated interferon + ribavirin (PR) for 12 weeks was 
compared with telaprevir (TVR)+PR for 48 weeks, and boceprevir (BOC)+PR for 48 
weeks. Sustained virologic response (SVR) rates were derived from clinical trials 
conducted in the HCV/HIV co-infected patient population. Transition probability, 
utility, and cost estimates were based on a literature review, public sources, and 
consensus by a panel of 4 hepatologists. Results: In the HCV/HIV co-infected 
cohort, the SOF-based regimen was associated with the lowest incidence of liver dis-
ease complications including hepatocellular carcinoma, decompensated cirrhosis, 
need for liver transplantation, and HCV-related death (reduction of 52% compared 
to TVR+PR and 65% compared to BOC+PR). In addition, patients receiving SOF+PR 
experienced more quality-adjusted life-years (QALYs), compared to those treated 
with other options (ranged from 0.63 to 1.10 QALYs). In terms of incremental qual-
ity adjusted life years gained, SOF+PR dominated over TVR+PR and BOC+PR. The 
sensitivity analysis indicated that the results were robust to changes in model 
inputs and assumptions, such as SVR rates, adverse event incidence, costs for treat-
ment monitoring and management of adverse events, and transition probability 
estimates. ConClusions: The SOF-based regimen of shorter duration, improved 
tolerability profile and high SVR rates was projected to yield the most favorable 
health and economic outcomes in the genotype 1 HIV and HCV co-infected popula-
tion compared to current treatment regimens using telaprevir or boceprevir.
PGI16
EConomIC EvaluatIons of trEatmEnts for Inflammatory bowEl 
dIsEasEs
Lachaine J., Miron A., Beauchemin C.
University of Montreal, Montreal, QC, Canada
objeCtives: In recent years, there has been a rapid growth in the development of 
novel biological treatments. Numerous economic evaluations have been performed 
to evaluate these treatments in inflammatory bowel diseases (IBD). The objective 
of this project was to explore the existing evidences regarding the cost-effective-
ness of treatments in IBD. Methods: A systematic review of the literature was 
50% of Hepatitis C patients in Turkey are female and the mean age of patients is 50. 
Approximately 60% of patients are treatment naïve. Approximately 900 liver trans-
plants are performed in Turkey per year and the success rate is around 85%. From 
the payer’s perspective, the average annual cost (excluding hepatitis C drug costs) 
of a chronic hepatitis C, compensated cirrhosis, decompensated cirrhosis, hepato-
carcinoma and liver transplant patient is USD 446.83, USD 577.56, USD 1984.39, USD 
2474.15, USD 42,469.27 respectively. ConClusions: Early diagnosis and treatment 
is crucial not only from the clinical perspective, but also from the cost perspective 
as a more severe disease costs significantly more.
PGI11
nEw all oral thEraPy for ChronIC hEPatItIs C vIrus (hCv): a Cost-
bEnEfIt analysIs
Orsi J.1, Einodshofer M.2, Kirkham H.1, Glover P.1, DuChane J.1
1Walgreen Co., Deerfield, IL, USA, 2Walgreen Co., Carnegie, PA, USA
objeCtives: New all oral HCV therapies are recognized as having higher cure rates 
than current standard of care (SOC) treatments. However, the cost-benefit of providing 
new all oral therapy versus SOC treatment is currently unknown. We undertook a 
study to examine the financial impact of anticipated all oral therapy for genotype 
1 disease and approved all oral therapy for genotypes 2 and 3 disease versus SOC 
treatments. Methods: We calculated pharmacy costs of approved drugs using 
wholesale acquisition costs, assuming a full course of therapy for genotypes 1, 2, 
and 3 diseases, respectively. Anticipated all oral therapy for genotype 1 was esti-
mated at 1.5 times the cost of all oral therapy for genotype 2. Costs for medical 
treatment over 14 years were based on published data for four therapeutic end-
points: cured, not cured and no cirrhosis, not cured with cirrhosis, not cured with 
cirrhosis and end stage liver disease. The study also accounted for the frequency 
of genotypes 1, 2, and 3 HCV disease within the U.S. population for pooled analysis 
across genotypes. Results: Genotype 1 all oral therapy is anticipated to provide 
overall cost savings of 13% compared to SOC. However, overall costs among approved 
genotypes 2 and 3 all oral therapy were 9% and 44% higher compared to SOC even 
with cure rates 20% and 18% higher. After accounting for genotype frequency 
within the general U.S. population, pooled analysis across genotypes showed a net 
cost savings of $1,248 per utilizing member per year for all oral treatment versus 
SOC. ConClusions: If our predicted cost of new genotype 1 therapy is accurate, 
cost savings will only be observed among the anticipated new all oral therapy for 
genotype 1 disease. However, these savings will provide a net cost savings across 
genotypes for all oral therapy compared to SOC treatment.
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objeCtives: To evaluate the cost-effectiveness of adalimumab plus standard of 
care (ADA+SOC) vs. SOC alone in moderate-to-severe ulcerative colitis (UC) patients 
with an inadequate response to SOC and to assess the total cost differences compar-
ing ADA+SOC to infliximab (IFX)+SOC and to golimumab (GOL)+SOC. Methods: 
A Markov model was developed to simulate the progression of patients receiv-
ing ADA+SOC or SOC over a 5-year time horizon from the Canadian publicly-
funded health system’s perspective, considering direct costs only in the base case. 
Transitional probabilities of pre-surgery and surgery-related states for ADA+SOC 
and SOC were derived from ADA trials and from literature. Health utility and cost 
inputs (medications, medical services, surgery, and surgery-related mortality) came 
mainly from literature. Additionally, a cost-minimization analysis (CMA) compared 
the total 5-year costs of biologics (ADA, IFX and GOL) assuming IFX and GOL having 
the same efficacy as ADA. Results were expressed in costs per quality-adjusted-life-
years (QALY) gained for ADA+SOC vs. SOC alone and in total cost differences for 
ADA+SOC vs. IFX+SOC and vs. GOL+SOC. Deterministic and probabilistic sensitivity 
analyses (DSA, PSA) were performed. Results: In the base case, the incremen-
tal costs per QALY gained for ADA+SOC vs. SOC were C$96,812 (in 2013 Canadian 
dollars [C$]). Results from DSA ranged from C$62,362 to C$109,461. PSA revealed 
that ADA+SOC was cost-effective in 58% and 81% of cases at C$100,000/QALY and 
C$120,000/QALY thresholds, respectively. The CMA predicted total cost savings of 
C$23,823 and C$4,279 comparing ADA+SOC to IFX+SOC and to GOL+SOC over 5 
years. DSA and PSA results showed that ADA+SOC led to cost savings in all scenarios 
comparing to IFX+SOC and in all but one DSA-based and all PSA-based scenarios 
comparing to GOL+SOC. ConClusions: The ADA+SOC strategy appeared to pro-
vide reasonable cost-effectiveness value compared with SOC alone and significant 
cost-saving benefits compared to IFX+SOC and GOL+SOC.
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objeCtives: The seroprevalence of hepatitis C virus (HCV) is 16-41% in United 
States (US) prisons, yet no standard protocols exist for HCV screening. The objective 
of our study was to evaluate the cost-effectiveness HCV screening in prisons and 
HCV prevention in society by interventions in prisons Methods: We developed 
an agent-based simulation model that simulated the transmission and progres-
sion of HCV disease in US population in prisons and society. Injection drug use 
was the main route of HCV transmission. Chronic stages of HCV were modeled 
as Markov states. We used US Department of Justice data to simulate movement 
of people between prisons and society. We evaluated two screening scenarios: no 
screening, and 1-time screening of all existing inmates followed by screening (and 
treatment) of any incoming inmate for 5 years (5YR screening). We projected the 
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objeCtives: Clostridium difficile infection (CDI) costs the US health care system over 
$3 billion annually. Current guidelines recommend metronidazole as first-line ther-
apy in most instances of CDI. However, vancomycin is recommended for recurrent 
CDI (RCDI). A growing body of evidence supports the use of fecal microbiota trans-
plantation (FMT) as a therapeutic option for RCDI. This study explores cost-effec-
tiveness of FMT and vancomycin versus metronidazole for initial CDI. Methods: 
We constructed a decision-analytic computer simulation using inputs from the pub-
lished literature to compare a 10-14-day course of oral metronidazole or vancomycin 
to FMT for initial CDI. Parameters included cure rates (range) for metronidazole [80% 
(65-85%)], vancomycin [90% (88-92%)] and FMT [91% (83-100%)]. The direct costs 
(range) of metronidazole, vancomycin and FMT, adjusted to 2011 dollars, were $57 
($43-72), $1347 ($1195-1499) and $1086 ($815-1358), respectively. Our effectiveness 
measure was quality-adjusted life years (QALYs). Analysis was performed from the 
3rd-party payer perspective and one-way and probabilistic sensitivity analyses were 
conducted. Results: Base case analysis showed that FMT ($1585, 0.242 QALYs) was 
more costly and more effective than metronidazole ($1167, 0.238 QALYs), yielding 
an ICER of $101,647/QALY. FMT was dominant (less expensive and more effective) 
compared to vancomycin ($1890, 0.241 QALYs). One-way sensitivity analyses showed 
that metronidazole dominated both competing strategies if its probability of cure 
was > 90%; FMT dominated if it cost < $667. In a probabilistic sensitivity analysis at 
a willingness-to-pay threshold of $100,000/QALY, metronidazole was favored in 50% 
of model iterations; FMT was favored in 45%. ConClusions: Our results suggest 
that metronidazole, as the first-line treatment for CDIs, may be less costly, but that 
FMT and vancomycin are more effective. However, FMT is less likely to be economi-
cally favorable, and vancomycin is unlikely to be favorable as first line therapy when 
compared to FMT, due to higher cost and less effectiveness.
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objeCtives: Based on a recent indirect treatment comparison, golimumab showed 
comparability in efficacy and safety to infliximab and superiority to adalimumab in 
efficacy in terms of sustaining clinical outcomes. For this reason, a cost-effectiveness 
(CE) analysis comparing the three anti-TNF-α agents was conducted. Methods: 
A Markov model was created to simulate patients over 10 years. The first admin-
istered intervention was any of the three biologics. Health states included clinical 
remission, clinical response, and relapse. Upon relapsing with the administered 
biologic, patients were assumed to transition into ‘relapse management’. Patients 
would then undergo colectomy and enter ‘post-colectomy remission’. Utilities were 
assigned separately for states before and after colectomy. Canadian cost estimates 
were used. Uncertainty around transition probabilities and cost estimates were 
incorporated. Sensitivity analyses included a societal perspective, varying discount 
rates, and time horizons, and ‘real world’ transition probabilities. Measures included 
total cost and utility over 10 years, mean incremental cost and utility per year, 
incremental CE ratios (ICERs), CE acceptability curves (CEACs) for golimumab and 
the CE frontier for all biologics. Results: In all analyses, golimumab yielded the 
lowest ICER. In the base case analysis, golimumab, infliximab, and adalimumab 
were associated with ICERs of approximately $40,000/QALY, $80,000/QALY, and 
$100,000/QALY, respectively. The CEAC for golimumab showed that a willingness-
to-pay threshold (WTPs) of $100,000/QALY was associated with a ~90% probability 
of being cost-effective. The cost-effectiveness frontier demonstrated that WTP 
thresholds greater than $25,000 showed that golimumab had the greatest prob-
ability of being cost-effective. Golimumab and infliximab displayed extended domi-
nance compared to adalimumab. Sensitivity analysis taking a societal perspective 
or using ‘real world’ transition probabilities reduced the ICERs by 20-40% for all 
biologics. ConClusions: Overall golimumab provides a cost-effective treatment 
option for patients who have had an inadequate response to conventional therapy 
for moderately to severely active ulcerative colitis.
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objeCtives: To evaluate the long-term impact of linaclotide on work productivity 
and activity impairment in adults with irritable bowel syndrome with constipa-
tion (IBS-C). Methods: In a 26-week phase 3 trial, 804 adults meeting modified 
Rome II criteria for IBS-C were randomized to oral once-daily 290-mcg linaclotide or 
placebo. The self-administered 6-item Work Productivity and Activity Impairment 
Questionnaire for IBS-C (WPAI:IBS-C) evaluated IBS-C-related absenteeism (work 
hours missed), presenteeism (lost productivity at work), overall work productiv-
ity loss (absenteeism + presenteeism), and daily activity impairment (housework, 
shopping, childcare, exercising, etc) over the previous week at baseline and weeks 
4, 8, 12, 16, 20, and 26 during the treatment period. Overall work productivity losses 
were converted into monetary values using the human capital method by multiply-
ing total hours lost by average hourly employment cost of a US employee ($31.16 
in September 2013). Results: Of 804 patients, 780 (97.0%) completed a baseline 
and ≥ 1 postbaseline WPAI:IBS-C assessment. Of these, 586 patients (75.1%) were 
currently employed. Linaclotide treatment was associated with statistically signifi-
cant reductions in presenteeism, overall work productivity loss, and daily activity 
conducted to identify economic evaluations of IBD therapy reporting incremental 
cost-effectiveness or cost-utility ratios (ICERs or ICURs). The literature search was 
performed using electronic databases. Searches were limited to full economic evalu-
ations published in English or French between 2003 and 2013. Cross-reference of 
retrieved articles was also performed to identify additional publications. Results: 
A total of 15,242 potentially relevant studies were identified. After screening titles 
and abstracts, 43 full-text articles were assessed according to the eligibility criteria 
and 35 studies were included. Among those, 3 studies assessed the economic impact 
of IBD treatments with a companion diagnostic test. A high proportion of economic 
evaluations was performed from a third party payer perspective (91%) and had time 
horizons of 1 year or less (46%). European, American and Canadian economic evalua-
tions accounted for 66%, 17% and 11% of the studies respectively. Treatment options 
under evaluation included azathioprine, infliximab, adalimumab, immunosuppres-
sant and mesalamine. Most included studies were cost-utility analyses (94%), with 
ICURs ranging from dominant to CAD$11,934,934/QALY. More specifically, treatment 
under investigation was dominant in 26% of the analyses and was cost-effective 
according to a CAD$50,000/QALY and a CAD$100,000/QALY threshold in 31% and 
65% of the analyses respectively. ConClusions: Several economic evaluations 
were conducted in the past years, with different parameters and results. As more 
treatment options become available, this review provides a comprehensive overview 
of evaluations previously performed and could be helpful in the realization of future 
economic evaluations.
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objeCtives: Valganciclovir (VGV) is an antiviral agent used as prophylaxis of 
cytomegalovirus (CMV) infection following solid organ transplant. Limited studies 
regarding CMV prophylaxis with VGV in liver transplant recipients (LTR) have been 
performed. This study is a cost effectiveness analysis of VGV prevention strategies 
in LTR from a payer perspective. Methods: We evaluated the cost of preventing 
hospitalization due to CMV in LTR at moderate to high risk of CMV. A decision 
tree model was constructed using TreeAge 2013. Data source for effectiveness was 
used from the results of our single-center retrospective analysis and cost data were 
from previously published data and the RedBook®. The model included costs of 
CMV prophylaxis, rates of CMV viremia, costs of outpatient treatment, and rates 
of inpatient admission due to CMV. We compared two protocols, one using lower 
doses and shorter duration of VGV prophylaxis (Group A) to a more recent protocol 
utilizing both higher doses and longer duration of VGV prophylaxis (Group B). Costs 
expressed in 2013 US dollars. Results: Costs associated with prophylaxis in group 
A were lower, despite a higher percentage of patients requiring treatment. Cost 
per-patient for prophylaxis in group A was $8,535.42 versus $14,926.73 in group 
B. In patients with CMV infection, 50% required hospitalization regardless of VGV 
prophylaxis group. Thus, 10% of patients in group A were hospitalized for treatment 
of CMV infection and only 4% of patients in group B required hospitalization. An 
ICER demonstrated that the prevention of one inpatient hospitalization due to CMV 
would cost $106,521.83. A one-way sensitivity analysis varying cost of VGV based 
on previously published costs demonstrated that the ICER for group B varies from 
$70,316 to $131,902. ConClusions: While the increased dose and duration of VGV 
is effective at preventing CMV infection and hospitalization, it is associated with 
a large incremental cost.
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objeCtives: Cigarette smoking increases the risk of postoperative complications. 
Preoperative smoking cessation programs may reduce surgical and post-operative 
complications, as well as the costs associated with treating them. We aimed to 
create an economic evaluation framework to estimate the potential value of pre-
operative smoking cessation programs for patients undergoing elective colorec-
tal surgery. Methods: A decision-analytic model was developed from the payer 
perspective to integrate the costs and incidence of post-operative complications 
for a patient undergoing elective colorectal surgery after a smoking cessation 
program versus usual care. Incidence of post-operative complications in the 
first 30 days for smokers and recent quitters were derived from a cohort of 1,543 
patients undergoing elective colorectal resections in Washington State’s Surgical 
Care and Outcomes Assessment Program (2011-2013). Costs, smoking cessation 
program efficacy and alternative probabilities were obtained from the literature. 
Sensitivity analyses were performed to account for uncertainty in these esti-
mates. Results: For a cohort of 5,000 patients undergoing a preoperative smoking 
cessation program, the base case estimates imply the prevention of 9 respiratory 
complications, 16 infectious complications, and 2 thromboembolic complications, 
but there would be 4 more cardiovascular complications. The total direct medical 
costs of complications for patients who underwent a preoperative smoking ces-
sation program were on average $138 lower per patient than those in the usual 
care group during the first 30 days after surgery. The model was most sensitive 
to smoking cessation program effectiveness, but remained dominant across all 
sensitivity analyses. ConClusions: A preoperative smoking cessation program 
is predicted to be cost-saving in the short term given the base case smoking ces-
sation efficacy of 22% if the cost of the intervention per patient is below $140. This 
framework allows payers to determine the value of smoking cessation programs 
of variable cost and effectiveness.
